{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091777","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.870527+00:00","generated_at":"2026-05-31T12:18:06.509118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace Medical Q2 revenue up 6% to $44.5M, net loss widens to $0.34/share, reaffirms FY guidance","bullets":["Revenue $44.5M (+6% YoY); gross margin 80.2% vs 81.7% prior year.","Net loss ($21.2M) or ($0.34)/share vs ($12.3M) or ($0.20)/share in Q2 2023.","Adjusted EBITDA loss ($8.7M) vs ($7.7M) a year ago; cash & equivalents $97.0M.","Full-year 2024 revenue guidance reaffirmed at $201M-$211M (7-13% growth); Adj. EBITDA expected to improve ~50%.","CEO highlights planned entry into minimally invasive metatarsal osteotomy market in Q4 2024 and 65 granted U.S. patents."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091777","json":"https://secwatch.observer/filing/0000950170-24-091777.json","markdown":"https://secwatch.observer/filing/0000950170-24-091777.md","text":"https://secwatch.observer/filing/0000950170-24-091777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/0000950170-24-091777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/tmci-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:06.509118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}